Privi Speciality Chemicals (PRIVISCL) investor relations material

Executive summary

• Achieved 24% year-over-year revenue growth in Q3 and 9M FY26, driven by a diversified product mix, operational excellence, and innovation focus.

• Outlined a three-phase expansion roadmap to increase capacity by 55% and broaden the specialty products portfolio over the next 2-3 years.

• Amalgamation of subsidiaries and acquisition of additional equity in Prigiv Specialties to unlock synergies and enhance operational efficiency.

• Unaudited consolidated and standalone financial results for Q3 and 9M FY26 were reviewed and approved, with an unmodified review conclusion from statutory auditors.

• Strategic focus on sustainability, capacity expansion, and becoming a world-class aroma chemical company.

Financial highlights

• Q3 FY26 consolidated revenue: Rs. 611.15 Cr (up 24% YoY); EBITDA: Rs. 158 Cr (up 37% YoY); EBITDA margin: 25.83%; PAT: Rs. 77.99 Cr (up 76% YoY).

• 9M FY26 consolidated revenue: Rs. 1,857.23 Cr (up 24% YoY); EBITDA: Rs. 481.04 Cr (up 47% YoY); PAT: Rs. 233.84 Cr (up 94% YoY); EBITDA margin: 25.9%.

• Adjusted Q3 PAT: INR 82 crore, up from INR 44 crore YoY, after one-time labor code adjustment and non-controlling interest.

• Basic and diluted EPS (consolidated) for Q3 FY26 was ₹19.97, up from ₹11.38 in Q3 FY25.

• One-time expense of Rs. 389.96 lakh due to new labor legislation in Nov 2025.

Outlook and guidance

• Targeting Rs. 5,000 Cr revenue and Rs. 1,000 Cr EBITDA within 3-4 years, with EBITDA margins expected to remain above 20%.

• Expecting 7% volume growth in the coming year, potentially reaching 11-15% depending on project ramp-up.

• Capacity utilization to remain around 85-90%, with new capacity coming online by March/April 2026.

• Continued investments in green chemistry, biotechnology, and digital transformation.